Literature DB >> 22005042

Small molecule positive allosteric modulation of TRPV1 activation by vanilloids and acidic pH.

Krisztian Kaszas1, Jason M Keller, Claudio Coddou, Santosh K Mishra, Mark A Hoon, Stanko Stojilkovic, Kenneth A Jacobson, Michael J Iadarola.   

Abstract

Transient receptor potential cation channel subfamily V member 1 (TRPV1) is a high-conductance, nonselective cation channel strongly expressed in nociceptive primary afferent neurons of the peripheral nervous system and functions as a multimodal nociceptor gated by temperatures greater than 43°C, protons, and small-molecule vanilloid ligands such as capsaicin. The ability to respond to heat, low pH, vanilloids, and endovanilloids and altered sensitivity and expression in experimental inflammatory and neuropathic pain models made TRPV1 a major target for the development of novel, nonopioid analgesics and resulted in the discovery of potent antagonists. In human clinical trials, observations of hyperthermia and the potential for thermal damage by suppressing the ability to sense noxious heat suggested that full-scale blockade of TRPV1 function can be counterproductive and subtler pharmacological approaches are necessary. Here we show that the dihydropyridine derivative 4,5-diethyl-3-(2-methoxyethylthio)-2-methyl-6-phenyl-1,4-(±)-dihydropyridine-3,5-dicarboxylate (MRS1477) behaves as a positive allosteric modulator of both proton and vanilloid activation of TRPV1. Under inflammatory-mimetic conditions of low pH (6.0) and protein kinase C phosphorylation, addition of MRS1477 further increased sensitivity of already sensitized TPRV1 toward capsaicin. MRS1477 does not affect inhibition by capsazepine or ruthenium red and remains effective in potentiating activation by pH in the presence of an orthosteric vanilloid antagonist. These results indicate a distinct site on TRPV1 for positive allosteric modulation that may bind endogenous compounds or novel pharmacological agents. Positive modulation of TRPV1 sensitivity suggests that it may be possible to produce a selective analgesia through calcium overload restricted to highly active nociceptive nerve endings at sites of tissue damage and inflammation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22005042      PMCID: PMC3251023          DOI: 10.1124/jpet.111.183053

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  35 in total

1.  Identification of an aspartic residue in the P-loop of the vanilloid receptor that modulates pore properties.

Authors:  C García-Martínez; C Morenilla-Palao; R Planells-Cases; J M Merino; A Ferrer-Montiel
Journal:  J Biol Chem       Date:  2000-10-20       Impact factor: 5.157

2.  Vanilloid receptor 1 regulates multiple calcium compartments and contributes to Ca2+-induced Ca2+ release in sensory neurons.

Authors:  László J Kárai; James T Russell; Michael J Iadarola; Zoltan Oláh
Journal:  J Biol Chem       Date:  2004-02-12       Impact factor: 5.157

3.  TRPV1-lineage neurons are required for thermal sensation.

Authors:  Santosh K Mishra; Sarah M Tisel; Peihan Orestes; Sonia K Bhangoo; Mark A Hoon
Journal:  EMBO J       Date:  2010-12-07       Impact factor: 11.598

4.  Acid potentiation of the capsaicin receptor determined by a key extracellular site.

Authors:  S E Jordt; M Tominaga; D Julius
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

5.  Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation.

Authors:  M Nolano; D A Simone; G Wendelschafer-Crabb; T Johnson; E Hazen; W R Kennedy
Journal:  Pain       Date:  1999-05       Impact factor: 6.961

6.  Anandamide activates vanilloid receptor 1 (VR1) at acidic pH in dorsal root ganglia neurons and cells ectopically expressing VR1.

Authors:  Z Olah; L Karai; M J Iadarola
Journal:  J Biol Chem       Date:  2001-05-01       Impact factor: 5.157

7.  Conserved Ca2+-antagonist-binding properties and putative folding structure of a recombinant high-affinity dihydropyridine-binding domain.

Authors:  I Huber; E Wappl; A Herzog; J Mitterdorfer; H Glossmann; T Langer; J Striessnig
Journal:  Biochem J       Date:  2000-05-01       Impact factor: 3.857

8.  Peripherally induced resiniferatoxin analgesia.

Authors:  John K Neubert; Laszlo Karai; Jae H Jun; Hyung-Suk Kim; Zoltan Olah; Michael J Iadarola
Journal:  Pain       Date:  2003-07       Impact factor: 6.961

9.  Deletion of vanilloid receptor 1-expressing primary afferent neurons for pain control.

Authors:  Laszlo Karai; Dorothy C Brown; Andrew J Mannes; Stephen T Connelly; Jacob Brown; Michael Gandal; Ofer M Wellisch; John K Neubert; Zoltan Olah; Michael J Iadarola
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

10.  Protein kinase C phosphorylation sensitizes but does not activate the capsaicin receptor transient receptor potential vanilloid 1 (TRPV1).

Authors:  Gautam Bhave; Hui-Juan Hu; Kathi S Glauner; Weiguo Zhu; Haibin Wang; D J Brasier; Gerry S Oxford; Robert W Gereau
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-01       Impact factor: 11.205

View more
  22 in total

Review 1.  A systematic review of the association between immunogenomic markers and cancer-related fatigue.

Authors:  L N Saligan; H S Kim
Journal:  Brain Behav Immun       Date:  2012-05-14       Impact factor: 7.217

2.  The fundamental unit of pain is the cell.

Authors:  David B Reichling; Paul G Green; Jon D Levine
Journal:  Pain       Date:  2013-12       Impact factor: 6.961

3.  Pain control through selective chemo-axotomy of centrally projecting TRPV1+ sensory neurons.

Authors:  Matthew R Sapio; John K Neubert; Danielle M LaPaglia; Dragan Maric; Jason M Keller; Stephen J Raithel; Eric L Rohrs; Ethan M Anderson; John A Butman; Robert M Caudle; Dorothy C Brown; John D Heiss; Andrew J Mannes; Michael J Iadarola
Journal:  J Clin Invest       Date:  2018-03-19       Impact factor: 14.808

Review 4.  Calcium signals that determine vascular resistance.

Authors:  Matteo Ottolini; Kwangseok Hong; Swapnil K Sonkusare
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2019-03-18

5.  Altered pharmacology of native rodent spinal cord TRPV1 after phosphorylation.

Authors:  A J Mogg; C E J Mill; E A Folly; R E Beattie; M J Blanco; J P Beck; L M Broad
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

6.  Vanilloids selectively sensitize thermal glutamate release from TRPV1 expressing solitary tract afferents.

Authors:  Mackenzie E Hofmann; Michael C Andresen
Journal:  Neuropharmacology       Date:  2015-10-22       Impact factor: 5.250

7.  Constrained TRPV1 agonists synthesized via silver-mediated intramolecular azo-methine ylide cycloaddition of α-iminoamides.

Authors:  Thomas O Painter; Krisztian Kaszas; Jacklyn Gross; Justin T Douglas; Victor W Day; Michael J Iadarola; Conrad Santini
Journal:  Bioorg Med Chem Lett       Date:  2013-12-21       Impact factor: 2.823

8.  Bi-directional modulation of food habit expression by the endocannabinoid system.

Authors:  Carol A Gianessi; Stephanie M Groman; Jane R Taylor
Journal:  Eur J Neurosci       Date:  2019-01-11       Impact factor: 3.386

9.  Investigating the involvement of TRPV1 ion channels in remote hind limb preconditioning-induced cardioprotection in rats.

Authors:  Puneet Kaur Randhawa; Amteshwar Singh Jaggi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-10-17       Impact factor: 3.000

10.  TRPV1 antagonist capsazepine suppresses 4-AP-induced epileptiform activity in vitro and electrographic seizures in vivo.

Authors:  Luis E Gonzalez-Reyes; Thomas P Ladas; Chia-Chu Chiang; Dominique M Durand
Journal:  Exp Neurol       Date:  2013-10-18       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.